Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered

Related Keywords

United States ,Denmark ,Copenhagen ,Køavn ,Lincoln Park ,Illinois ,Russia ,Chicago ,Ukraine ,American ,Bo Karmark ,Corey Davis ,Lars Wegner ,Lincoln Park Capital Fund ,Exchange Commission ,Lifesci Advisors ,Company Adss ,Company The Ordinary ,American Depositary Shares ,Lincoln Park Capital ,Spark Capital ,Evaxion ,Biotech ,Ecures ,Equity ,Financing ,Billion ,Rom ,Lincoln ,Park ,Capital ,